Navigation Links
Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
Date:9/30/2010

biopharmaceutical company focused on allergy, today announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines.' In recent weeks, Circassia has initiated phase II clinical testing of its grass allergy (hayfever) therapy, begun the final stage of phase II testing with its ragweed allergy treatment and progressed phase III development plans for its cat allergy therapy. This progress builds on four earlier successful phase II studies of Circassia's ToleroMune(R) technology, which scientifically validated the use of novel T-cell vaccines in treating allergies and identified the optimal dosing approach.

Following these advances, Circassia now has four allergy therapies in late-stage development:

1. Cat allergy. The company's most advanced T-cell vaccine is currently completing its final phase II study. The trial, which includes over 200 patients in Canada, is the first to test Circassia's room-temperature-stable ToleroMune formulation. In parallel, Circassia is progressing phase III development plans for its cat allergy therapy, following a positive endorsement from the European Medicines Agency's scientific advice process.

2. Ragweed allergy. Circassia has initiated the final phase II trial with its ragweed allergy ToleroMune therapy. This 275-patient trial builds on a recently completed phase II study, which demonstrated the potential clinical benefits Circassia's T-cell vaccine can offer ragweed allergy sufferers.

3. Grass allergy (hayfever). Circassia recently initiated phase II clinical testing of its grass allergy T-cell vaccine. Results from the study are anticipated in 2011.

4. House dust mite allergy. Circassia's therapy for house dust mite allergy began phase II testing in early 2010. The initial study is near completion.

"These recent clinical advances demonstrate Circassia's commitment to bringing its unique T-cell allergy vaccines to market as rapidly as poss
'/>"/>

SOURCE Circassia Ltd
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine
2. Circassia Acquires North American and Japanese Rights to Dopexamine
3. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Madison, WI (PRWEB) May 24, 2013 ... to the discovery and development of calcium-binding proteins ... publication of safety assessment study of apoaequorin ... an international journal published for the British Industrial ... the study was to investigate potential adverse effects, ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... will present at the Jefferies 2013 Global Healthcare Conference ... Hyatt New York. Richard Smith ... Hai Tran , Chief Financial Officer, will ... Eastern Daylight Time.   About BioScrip ...
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)... Calif. , May 23, 2013 ... a strategic alliance with DAK Renewable Research to ... corn oil yield. VG Energy is a majority ... Pink: VGLS). VG Energy,s exclusively licensed ... increase the oil yield in plants, possessing a ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3
... TOKYO, Japan, October 14 ... a biopharmaceutical company,today announces the assignment of the ... Limited, a UK biotechnology company and subsidiary of,PepTcell ... a well-known,drug, were shown by Sosei to have ...
... , SAN DIEGO, Oct. 13 SpectraScience, Inc. (OTC ... company, today announced that it has engaged Bielderman BVBA, ... clinical process for its Barrett,s esophageal cancer application under ... be used in the Company,s application to the Food ...
... (Nasdaq: CPHD ) today announced that it will report ... on Wednesday, October 28, 2009, after the close of the ... 2 p.m. Pacific Time on Wednesday, October 28, 2009, to ... visit Cepheid,s website at www.cepheid.com/investors at ...
Cached Biology Technology:Sosei Announces Deal With UK Biotech Company 2SpectraScience Engages European Contract Research Organization to Manage Clinical Trials 2SpectraScience Engages European Contract Research Organization to Manage Clinical Trials 3Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast 2
(Date:5/22/2013)... whole organism, as they may lead to life-threatening illnesses ... report how byproducts of respiration cause mispairing of subunits ... cells controls the form and function of every cell ... encoded in the linear sequence of the four subunits ... guanine (G) and thymine (T). Random changes in the ...
(Date:5/22/2013)... known as phthalates (pronounced THAL-ates) are odorless, colorless ... flooring, plastic cups, beach balls, plastic wrap, intravenous ... and Preventionthe bodies of most Americans. Once perceived ... A growing collection of evidence suggests dietary exposure ... mix with food) may cause significant metabolic and ...
(Date:5/21/2013)... When infections occur in the body, stem cells ... multiplying and differentiating into mature immune cells that ... inflammation can deplete these cell populations, potentially leading ... as cancer. Now, a team of researchers led ... (Caltech) has found that, in mouse models, the ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Keeping stem cells strong 2
... 2011) − Scientists at the University of Kentucky have discovered ... up blood clots, speeds up the progress of prion diseases ... a promising new target for the development of drugs to ... author Chongsuk Ryou, a researcher at the UK Sanders-Brown Center ...
... Based on its recent analysis of the ... Cardiocom with the 2011 North American Frost & ... clinical telehealth services that offer significant cost savings ... http://photos.prnewswire.com/prnh/20081117/FSLOGO ) Cardiocom combines advanced telehealth ...
... N.C. The recipe for making one species into ... being on different islands or something else that discourages ... the case of common Texas wildflowers that share meadows ... Duke University graduate student Robin Hopkins has found the ...
Cached Biology News:Research identifies drug target for prion diseases, 'mad cow' 2Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 2Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 3Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 4Wildflower colors tell butterflies how to do their jobs 2
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
PlusOne Acrylamide PAGE, 1 kg. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
... The GenoStat Inducible Expression System provides ... in mammalian cells and is capable of ... control is mediated by the highly specific ... chimeric bipartite nuclear receptor complex. Gene expression ...
... 53 new primer sets added in Dec 2005 ... 3 hours , Detection from as ... , Specific primers available for hundreds of ... real-time or end-point RT-PCR , Ideal ...
Biology Products: